CR Bard to market CorMedica's heart laser system:
This article was originally published in Clinica
Executive Summary
CR Bard is to have exclusive, worldwide distribution rights to CorMedica's systems for catheter-based, percutaneous transluminal endomyocardial revascularisation (PTER) procedures. The products treat serious coronary artery disease by delivering laser energy through a catheter to create channels in the heart muscle. CorMedica is a privately-held company based in Natick, Massachusetts.